PCSK9 inhibition & Cardiovascular Outcomes: Review of lipid targets and treatment strategiesOnline-CME - This course consists of three lectures.
This CME accredited course consist of 3 separate lectures. View all 3 lectures and earn 1 CME credit. the content of this course is based on a CME symposium held on August 27, 2017 at the ESC congress in Barcelona
This curse consist of the following lectures
- Understanding new PCSK9 outcome data: From the LDL-C hypothesis to LDL-c causality- by John Chapman, PhD - Paris, France
- PCSK9 inhibition across a wide spectrum of patients: For whom is it efficacious? - by Kees Hovingh, MD - Amsterdam, The Netherlands
- PCSK9 inhibition & CV events: Review of recent and upcoming hard endpoint outcome trials - by Peter Sever, MD - London, United Kingdom
Educational objectives of this course are to:
- Understand the unmet need for additional LDL-C-lowering therapies beyond current optimal statin-based therapy as a strategy for addressing lipid-related CV risk in patients at increased CV risk and with FH
- Understand the mechanisms and potential applications of emerging therapies to lower LDL through novel approaches that can be used in combination with statin therapy
- Describe the potential impact of PCSK9-based therapies in development in patients who require additional LDL-C reduction
- To explore treatment options in a statin-intolerant high risk patient in order to reach LDL-C goal
- Compare and evaluate evidence from recent clinical trials of novel agents in clinical development and assess their impact on lipids and cardiovascular risk
- Understand the implications of new ESC guidelines for lipid management
This online course is accredited by the European Board for Accreditation in Cardiology (EBAC) for 1 hour of external CME credit(s).
This is available as accredited online CME for members. Click the button below to enroll:Enroll